Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the commercial launch of Zenith genomics, its next-generation whole genome sequencing assay ...
CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results